В статье представлены общие подходы, применяемые в последнее время для усиления чрескожного переноса лекарственных субстанций при аппликации трансдермальных терапевтических систем. Подробно рассмотрены химические, физические и механические способы усиления транспорта высокомолекулярных соединений через кожу.
26 February 2020 in Drug development & registration
Введение. Широкое применение в медицинской практике иммуномодуляторов способствует разработке их новых лекарственных форм. Цель. Целью данной работы является разработка трансдермальной терапевтической системы (ТТС) Галавит® и исследование in vitro диффузии ЛВ из нее через мембрану Strat-M. Материалы и методы. Лекарственной субстанцией служил Галавит® в виде порошка для приготовления раствора для внутримышечного введения («СЭЛВИМ», Россия). В качестве вспомогательных веществ применяли физиологический раствор, додецилсульфат натрия, масло абрикосовых ядер, эмульгатор Decaglyn PR-20 и другие. Для изготовления эмульсионных композиций использовали диспергатор Heidolph DIAX900 (Германия) и ультразвуковой гомогенизатор Heilscher UIS250V (Германия). Время расслоения и размер частиц эмульсионных композиций определяли на анализаторе дисперсий LUMiSizer (LUM, Германия). Исследования диффузии Галавит® из ТТС через мембрану Strat-M (25 мм в диаметре, Merck Millipore) проводили на анализаторе диффузии Copley (Великобритания). Количественное определение Галавит® в модельных средах выполняли методом спектрофотометрии (UV-2600 Shimadzu, Япония) в диапазоне длин волн 294–298 нм. Результаты и обсуждение. В ходе исследования определены характеристические параметры эмульсионных композиций: размер частиц варьировал от 0,1 до 2 мкм, время расслоения – от 9 до 95 мин в зависимости от состава. Максимальный выход лекарственного вещества из ТТС через мембрану составил 30 %. Заключение. В модельных экспериментах показана возможность трансдермального переноса Галавит® из ТТС.
Producing a tissue-engineered pancreas based on a tissue-specific scaffold from a decellularized pancreas, imitating the natural pancreatic tissue microenvironment and the islets of Langerhans, is one of the approaches to treating patients with type 1 diabetes mellitus (T1DM). The aim of this work was to investigate the ability of a fine-dispersed tissue-specific scaffold (DP scaffold) from decellularized human pancreas fragments to support the islets’ survival and insulin-producing function when injected in a streptozotocin-induced diabetic rat model. The developed decellularization protocol allows us to obtain a scaffold with a low DNA content (33 [26; 38] ng/mg of tissue, p < 0.05) and with the preservation of GAGs (0.92 [0.84; 1.16] µg/mg, p < 0.05) and fibrillar collagen (273.7 [241.2; 303.0] µg/mg, p < 0.05). Rat islets of Langerhans were seeded in the obtained scaffolds. The rats with stable T1DM were treated by intraperitoneal injections of rat islets alone and islets seeded on the DP scaffold. The blood glucose level was determined for 10 weeks with a histological examination of experimental animals’ pancreas. A more pronounced decrease in the recipient rats’ glycemia was detected after comparing the islets seeded on the DP scaffold with the control injection (by 71.4% and 51.2%, respectively). It has been shown that the DP scaffold facilitates a longer survival and the efficient function of pancreatic islets in vivo and can be used to engineer a pancreas.
1 September 2014 in Inorganic Materials: Applied Research
The construction and composition of the bromocain matrix transdermal therapeutic system (TTS) based on microemulsion preparation are presented. Comparative study of the bromocain TTS functional properties in vitro and in vivo with and without the presence of the transfer activator docusate sodium salt (DSS) in the preparation was conducted using the high-performance liquid chromatography method. It was shown that the introduction of the transfer activator in the TTS increased both the release of the active ingredient from the drug and the rate of diffusion and, consequently, the amount of the diffused active pharmaceutical ingredient (API). The diffusion rate of 120.09 ± 21.6 and 332.34 ± 70.7 μg/(h cm2) was reached on addition of the DSS to the TTS with active surface area of 10 cm2 and bromocain dose of 50 and 100 mg, respectively. The diffusion rates were only 23.09 ± 3.7 and 31.34 ± 8.1 μg/(h cm2) in the absence of the activator. It was established that the initial bromocain content in the TTS did not affect the diffusion rate of the drug through the skin in the absence of the activator.
1 January 2021 in Russian Journal of Transplantology and Artificial Organs
Introduction. Immunomodulator Galavit (R) is a promising domestic drug for the prevention and treatment of various infectious diseases. Earlier, the authors have developed and investigated in vitro its new dosage form - transdermal therapeutic system (TTS). Positive results from experiments made it possible to proceed to the study of the pharmacokinetic parameters of Galavit (R) TTS in animals. Objective: to compare the pharmacokinetic parameters of intramuscular and transdermal administration of immunomodulator Galavit (R) in animal experiments. Materials and methods. Sodium aminodihydrophthalazinedione was used as a substance in the form of a powder to prepare a solution for intramuscular administration of 100 mg (trade name Galavit (R), manufacturer SELVIM LLC). The pharmacokinetics of transdermal and intramuscular injections were studied in male Chinchilla rabbits weighing 4.5-5.0 kg. Serum sodium aminodihydrophthalazinedione concentrations in animals were determined by high-performance liquid chromatography using a specially developed technique. Results. In contrast to the injection method, a prolonged and uniform inflow of the drug substance (MP) into the body is observed for percutaneous administration of sodium aminodihydrophthalazinedione. The maximum serum Galavit (R) concentration for a 40 mg dose (0.172 +/- 0.054 mu g/mL) and for a 80 mg dose (1.16 +/- 0.22 mu g/mL) remained at a constant level for 9 and 8 hours, respectively. The relative bioavailability of the Galavit (R) transdermal therapeutic system was 0.65 and 1.06 for the same doses. Conclusion. Application of Galavit (R) 80 mg transdermal therapeutic system provides bioavailability that is similar to the intramuscular administration of this drug at the same dose. At the same time, its maximum serum concentration significantly decreases and the retention time of Galavit (R) in the body increases by more than 10 times, which can contribute to prolongation of the drug effect. Due to the current growing interest in the use of immunomodulator Galavit (R) for coronavirus infection COVID-19, the development and study of a new dosage form is a promising task.
18 May 2019 in Russian Journal of Transplantology and Artificial Organs
Aim: to develop the emulsion transdermal therapeutic system (TTS) of cyclosporine and the research of its diffusion from TTS.Materials and methods. The quantitative evaluation of cyclosporine in model media was performed on liquid chromatograph Agilent 1100 G1311 with spectrophotometric detector G1315B (Germany). For the production of the emulsion matrix, the Heidolph DIAX900 disperser (Germany) and the ultrasonic homogenizer Hielscher UIS250V (Germany) were used. The cyclosporine diffusion from TTS through Strat-M membrane (25 mm in diameter, Merck Millipore) was studied using Copley diffusion analyser (Great Britain).Results. Using the developed method of micro-HPLC, it was established that the amount of cyclosporine passed through the Strat-M membrane over 24 hours from 10 sm2 TTS, containing 173 mg of the substance, was 5.9 mg. The estimated blood concentration is ~ 50 ng/ml which corresponds to the therapeutic maintenance blood concentration during organ transplantation (50–75 ng/ml).Conclusion. The model studies demonstrate the possibility of the cyclosporine transdermal transfer.